Back to News
Dec 12, 2025 4:00 PM

European Regulator Backs Approval Of Novo Nordisk High-Dose Wegovy

On Friday, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Novo Nordisk A/S’ (NYSE:NVO) higher dose of Wegovy (semaglutide 7.2 mg).

Novo Nordisk has also applied to the EMA for a single-dose device to deliver Wegovy 7.2 mg.

Additionally, semaglutide 7.2 mg is currently under review in the U.S., U.K., and several other countries.

Also Read: FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch

What Data ...